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Abstract: 
The recent regulatory changes enacted by the Centers for Medicare and Medicaid 
Services (CMS) have identified hospital readmission rates as a critical healthcare quality 
metric. This research focuses on the utilization of pay-for-performance (P4P) 
mechanisms to cost effectively reduce hospital readmission rates and meet the 
regulatory standards set by CMS. Using the experimental economics laboratory we find 
that both of the P4P mechanisms researched, bonus and bundled payments, cost-
effectively meet the performance criteria set forth by CMS. The bundled payment 
mechanism generates the largest reduction in patient length of stay (LOS) without 
altering the probability of readmission. Combined these results indicate that utilizing P4P 
mechanisms incentivizes cost effective reductions in hospital readmission rates. 
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1. Introduction 
Recently the Institute of Medicine estimated the amount of wasted, excess cost of 
healthcare to be approximately $765 billion in 2009 (Institute of Medicine 2012). The 
growth in our health expenditures relative to GDP makes the United States a clear global 
outlier (Chandra and Skinner 2012), but the care being provided merely places us in the 
middle of the pack (Fuchs and Millstein 2011). The United States is faced with the 
challenge of not only decreasing the cost of providing care to its population, but also 
increasing the quality that is provided. The Centers for Medicare and Medicaid Services 
(CMS) has recently identified hospital readmission rates as a critical healthcare quality 
metric within the United States and taken regulatory steps to incentivize hospitals to 
increase their performance. The incentive mechanism utilized by CMS penalizes 
hospitals that do not meet their performance targets (i.e., readmission rates that exceed 
expected levels). Recently, the penalties used by CMS amount to a 1% reduction in 
reimbursement rates for hospitals that have “too many” patients being readmitted within 
30 days of hospitalization. The outcome was a total penalty of $280 million in 2013 and 
the percentage is expected to increase to 3% in 2015 (CMS 2015, Health Affairs 2013).1  
The penalties enacted by CMS come at a considerable cost to hospitals, as any 
additional preventive care must be covered by the current prospective payment 
scheme. 2  This research focuses on the utilization of pay-for-performance (P4P) 
mechanisms that are intended to lower hospital costs without increasing hospital 
readmission. The incentive mechanisms are designed to better align the financial 
interests of the physicians and the hospital. The performance metrics we use are 
hospital length of stay and readmission rates. Given the current prospective payment 
scheme used in the United States, a reduction of either one without increasing the other 
improves the quality of care at lower costs.  
We report the results from two experiments. Experiment 1 investigates the 
efficacy of two alternative P4P mechanisms, bonus and bundled payments, that tie 
physicians’ payments to performance. We ask whether the P4P mechanisms can be 
                                                        
1 The current regulations only address hospital readmissions for patients being treated for three 
medical conditions: heart attack, heart failure and pneumonia. The $280 million in penalties was 
spread out across over 2,200 hospitals in fiscal year 2013 (Health Affairs 2013). The scope, and 
therefore the penalties, of the CMS regulations are expected to increase in the future (CMS 
2015). 
2 The prospective payment scheme is implemented in the United States using Diagnosis Related 
Group (DRG) payments.  A hospital receives a flat DRG payment for each patient and procedure 
event with the payment not varying by the patient’s hospital length of stay.  An alternative to this 
is the fee-for-service (FFS) system where a hospital receives payment for each service provided. 
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used to reduce hospital costs, without increasing readmissions, compared to baseline 
outcomes with fee-for-service compensation.3 Experiment 2 investigates the robustness 
of the P4P incentive effects in an environment with richer information provided to 
physicians. Our results suggest that either bonus or bundled P4P physician 
compensation reduces hospital length of stay for patients but the bundled compensation 
does so without increasing readmission rates. Additional reductions are observed when 
we combine the bundled payment mechanism with providing physicians information on 
the likelihood of readmissions.  
Design of an efficient healthcare system, including physician compensation and 
insurance markets, has been extensively studied in the economics literature beginning 
with the work of Arrow (1963). In light of the asymmetric information and informational 
uncertainties in the healthcare market, Arrow (1963) highlighted the need for payment of 
services, either to physicians or incorporated into insurance markets, to be based on the 
efficacy of a patient’s treatment. This form of compensation is rarely if ever used in 
current practice. P4P mechanisms are an attempt in this direction as many P4P 
programs are based on the quality of care, which presumably is correlated with patient 
health outcomes. This said, the most common forms of healthcare payment are fee-for-
service, prospective payment (i.e., diagnosis related groups or DRGs), patient-based 
capitation (i.e., health maintenance organizations or HMOs) and salaries. The existing 
economic literature, as discussed below, has compared these incentive structures 
extensively. 
The next section focuses on the literature and discusses the contributions of our 
research. Sections 3 and 4 report on the details and results of Experiment 1 that we 
conduct to investigate the efficacy of P4P programs to cost-effectively lower hospital 
readmission rates with patient information from electronic medical records, as currently 
provided in hospitals. Section 5 reports on the efficacy of P4P mechanisms in a richer 
information setting. The final section summarizes our research and provides some 
additional guidance regarding future research needs in this area. 
 
2. Literature Review 
In this section we review theoretical, empirical and experimental studies on the effect of 
payment schedules on physicians’ choice of care for their patients. The main finding is 
                                                        
3 Our baseline treatment is fee-for-service because prospective payments predominately apply to 
hospital compensation, whereas physicians still receive fees for the services they provide. 
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that physicians’ selections of diagnostic methods, referrals, and care treatments vary 
greatly across different payment schemes. 
 
2.a Theoretical Studies 
Allard, et al. (2011) theoretically investigate the incentives and outcomes of general 
practitioners (GPs) under three compensation schemes: (1) fee-for-service (FFS), (2) 
capitation, and (3) fundholding.4 Fee-for-service pays for all services rendered, capitation 
pays a flat fee per patient per year with the GPs being responsible for all care costs they 
provide, whereas fundholding builds on capitation by making GPs financially responsible 
not only for the care they provide but also for the care provided by specialists. A fee-for-
service payment mechanism creates an incentive for physicians to over-treat their 
patients, which increases treatment costs but not necessarily the quality of care. The 
capitation payment scheme pays physicians a flat rate for each patient under their care; 
it was introduced to internalize the incentive problems of over-treatment associated with 
FFS.  A central research question is whether the compensation scheme, combined with 
GP ability and preferences, alters the treatment and referral rates of “gatekeeper” GPs.  
Allard, et al. (2011) show that: (i) under a capitation scheme GPs are better off 
referring their patients to a specialist to minimize their own treatment costs; (ii) GPs 
compensated under a fee-for-service system are less likely to refer a patient; and (iii) 
under some circumstances referral rates are similar for fundholding and fee-for-service.  
This arises because fundholding compensation induces GPs to reduce the costs that 
may be incurred if a patient is referred to specialists when the expected costs of the 
specialists exceed their own. Extrapolating from earlier work on physician partnership 
revenue sharing, Gaynor and Gertler (1995) predicted that physicians would dramatically 
reduce their effort levels under a capitation payment model whereas FFS payment 
encourages excessive effort levels, a moral hazard effect. An extreme form of capitation 
would be to provide physicians with a flat salary independent of the number of patients 
they serve. Woodward and Warren-Boulton (1984) offer a theoretical analysis of this 
                                                        
4 Fundholding was created under the changes to the United Kingdom’s health care system in 
1991 in an effort to separate the physician and hospital care markets. For a more detailed review 
of the fundholding program see Croxson, et al. (2001) and Matsaganis and Glennerster (1994).  
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compensation scheme and show that it induces physicians to provide less than the 
efficient level of care.5  
Another payment schedule, known as a prospective payment scheme, was 
enacted by CMS in the early 1980s in the form of diagnosis related group (DRG) 
payments. Under this compensation scheme the hospital receives a flat payment that 
they must use to cover the expenses of treating a patient (i.e., services provided by the 
physician) but the flat payment differs across DRGs. Ellis and McGuire (1986) 
theoretically show that the DRG payment scheme leads to an inefficient supply of 
hospital services unless the physician serves as a perfect agent for the patient and is not 
influenced by the hospital’s profit motive. They argue in favor of a mixed-payment 
scheme as the most theoretically efficient payment scheme (Ellis and McGuire 1986).6  
The two P4P schemes we experimentally investigate are similar in spirit to the 
compensation schemes discussed by Ellis and McGuire (1986) as the payments 
received by hospitals and physicians are more closely linked than under a conventional 
prospective payment scheme. 
 
2.b Empirical Studies 
In an empirical study directly relevant to our research, Moreno-Serra and Wagstaff 
(2010) analyze the performance of FFS and prospective payment mechanisms, relative 
to the use of historical budgets, using a panel data set of 28 European and Central Asian 
countries for 1990-2004. They find higher admission rates to hospitals under the FFS 
programs but no impact on the average hospital length of stay for patients. On the 
contrary, the prospective payment schemes had no effect on inpatient admissions but 
the average length of stay was reduced. In a later study, Clemens and Gotlieb (2014) 
estimate that a two percent increase in prospective payment compensation rates results 
in a three percent increase in physician care, defined as the number of relative value 
units (RVUs) provided to a patient. Their finding provides further evidence that 
physicians respond positively to increases in compensation rates. 
 Pay-per-performance (P4P) mechanisms are being increasingly advocated 
because they are believed to incentivize physicians and hospitals to provide better 
                                                        
5 The empirical literature in this area reports mixed results. The findings of Barro and Beaulieu 
(2003) and Hickson et al. (1987) clearly support the hypotheses of Woodward and Warren-
Boulton (1984) but the work of Grytten and Sørensen (2001) does not. 
6 In a mixed-payment scheme a portion of hospital expenses is covered via prospective payment 
whereas the rest is covered from a cost compensation model where payments are received 
based on the cost of care, a form of FFS. 
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quality care.7 However, empirical findings on the quality of care are mixed with some 
studies reporting support for P4P (Beaulieu and Horrigan 2005, Lindenauer et al. 2007) 
and others finding no effect (Rosenthal and Frank 2006).8 Beaulieu and Horrigan (2005) 
research the effectiveness of quality-based annual bonuses to incentivize higher quality 
of care for diabetic patients and find that the P4P mechanism increased the patient’s 
health for five of the six reported measures. 9  Lindenauer et al. (2007) study the 
effectiveness of quality-based bonuses based on a physician’s performance relative to 
their peers. They report improvements in quality for seven of their ten measures of 
hospital performance. In contrast, Mullen, et al. (2010) report that they failed to find 
evidence that P4P programs result in any substantial improvements in patient care.  
They look at whether P4P programs increased the quality of healthcare across a broad 
suite of P4P incentives in California and the Pacific Northwest. The P4Ps under study 
provided bonuses to physicians based on whether they met specific clinical quality 
metrics. An important feature of the Mullen, et al. (2010) study for our research is that 
one of the metrics they used was hospital readmissions for outpatient care; they find no 
conclusive evidence that the (bonus) P4P mechanism lowered readmission rates.  
Several P4P mechanisms have been implemented in the United Kingdom and 
Canada. In 2004 the United Kingdom initiated a P4P program that awarded points to 
practicing physicians based on 146 quality indicators that were used to generate income 
for the physicians. The government expected physicians to reach 75% of the total 
achievable points, but the median physician hit 96.7% of the total (Doran, et al. 2006). 
This resulted in a substantially higher cost for the government than anticipated but the 
incentives did generate a change in physician practice consistent with the objectives of 
the program. In Ontario, Canada eleven different P4P mechanisms were introduced 
between 1998 and 2008 (Li, et al. 2014). Six of these P4P mechanisms were special 
payments made for taking specific actions whereas five were bonus mechanisms based 
on performance targets. The results were mixed as the bonuses were effective for some 
procedures (i.e., pap smears, mammograms, flu shots) but not for others (i.e., palliative 
care, prenatal care, home visits) (Li, et al. 2014).  
                                                        
7 Performance incentives are not limited to the health care literature.  For example, Bandiera, et 
al. (2005, 2009) investigate the impact that alternative payment mechanisms have on workforce 
productivity using field experiments. 
8 Despite these mixed results, Hemenway et al. (1990) find that P4P mechanisms were effective 
in incentivizing physicians to increase billings at for-profit emergency rooms. Physicians in their 
study strongly responded to financial incentives that affected their earnings.  
9 A caution is warranted as enrollment in the P4P was not random. 
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There are a number of limitations of P4P programs that may explain why the 
results have been mixed. Many of these studies are small in scale, based on Medicare 
patients, and have short intervention time periods (Rosenthal and Frank 2006). In 
addition, in the U.S. health care system physicians receive compensation for their 
services from a large number of providers, and it is possible that the failure to incentivize 
the physicians can be attributed to interventions being too small relative to other 
payments received (Rosenthal and Frank 2006). The experiments we conduct will allow 
us to control for some of these factors (i.e., tangible incentives, representative patient 
sample, well constructed treatment and control groups) and to better isolate the efficacy 
of P4P programs. Our experiments use a sample of experimental healthcare providers 
randomized over three different compensation environments tied to effective care of the 
patients and relative performance. 
There are two additional limitations of P4P that we will not be able to address 
with our experiments but that we can control for in our design: the multitasking nature of 
a physician’s decision space and the imperfect matching of patients and physicians. 
Eggleston (2005) illustrates that a physician has an incentive to increase the quality of 
care in the rewarded dimensions of a P4P program at a cost of reducing the quality of 
care in other dimensions of the service they provide because they are multitasking. This 
has the potential to have a negative welfare effect. Imperfect matching between patients 
and physicians reduces the ability of the P4P mechanism to incentivize the appropriate 
physicians that the program targets. Using Medicare claims data, Pham et al. (2007) 
show that no more than half of patients’ visits are with physicians who would be 
responsible for them under a P4P program; this is attributed to instability in the patient-
physician matches. Therefore, it may be difficult under current P4P programs to account 
for dispersion of care. The experiment we conduct controls for these factors. In the 
experiment our physician subjects are responsible for making only one decision, to 
discharge or not to discharge a patient, thus eliminating the effects of physician 
multitasking on outcomes.  Furthermore, each physician subject in the experiment is 
responsible for all the patients under her care thus ensuring stability in the patient-
physician pairing. 
 
2.c Experimental Studies 
The experiments we conduct are not the first to investigate the effect of alternative 
payment mechanisms on physician behavior (see, for example, Hennig-Schmidt, et al. 
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2011; Fan, et al. 1998). However, to the best of our knowledge, we are the first to 
investigate the efficacy of P4P mechanisms that attempt to more closely align the 
physician and hospital incentives that are being increasingly proposed as a solution to 
the rift between the cost of patient care and the quality delivered.  
Fan, et al. (1998) conduct an experimental analysis of physician decisions under 
two alternative payment mechanisms: (1) expenditure targets and (2) expenditure caps. 
Under an expenditure target payment mechanism physicians individually profit maximize 
whereas under an expenditure cap model physician payment is determined also by the 
actions of other physicians. Their results indicate that the level of health services is 
greatest under the cap system given the same level of budget. Hennig-Schmidt, et al. 
(2011) conduct an experiment using 42 medical students to investigate the impact that a 
FFS and capitation (CAP) payment mechanism have on: (1) the supply of medical 
services; (2) the relationship between patient health status and selected treatments; and 
(3) the resulting health status of patients. There were 15 hypothetical patients in their 
experiments divided into 3 types of healthcare needs: low, moderate, and high need. 
They find that more care is provided under a FFS than CAP system, implying that 
patients are under-served under the CAP and over-served under FFS, relative to the 
induced optimal treatment benefits for the patient.10 The finding is consistent with the 
predictions of Gaynor and Gertler (1995). They also find that a patient’s health status 
influences the provision of care: patients with low to moderate health needs are over-
served under a FFS and those with high needs are underserved under the CAP system.  
 
3. Experiment 1: P4P Compensation and EMR Information 
We experiment with hospital discharge decision making using medical students enrolled 
in a large medical school within the southeastern United States. At the beginning of each 
experimental session, the subjects were welcomed to the decision laboratory by one of 
the researchers who explained that the research was supported by an NIH grant with the 
purpose of investigating discharge decision making.11 Subjects read and signed the IRB-
approved consent form and subsequently began reading the subject instructions on their 
                                                        
10 In the Hennig-Schmidt, et al. (2011) experiments a patient benefit function has diminishing 
marginal benefits. All subjects are aware of the benefits each treatment will provide to their 
hypothetical patient as well as their internal costs and benefits.  
11 The lead point of contact for the experiments was the PI on the NIH grant funding our research 
at the southeastern United States medical school where the experiments were conducted. 
 7 
computer monitors.12 For each “experimental day”, subjects reviewed individual patient 
data from a list on the screen that displayed fictitious patient IDs and names along with 
real summary information from three distinct patient charts. The real summary 
information included the patient’s age, sex, and current length of stay in the hospital (up 
to the current experimental day) taken from de-identified electronic medical records 
(EMRs). For any patient on the list, the subject was presented with a series of charts that 
were facsimiles of the patient charts in the EMR, retaining the de-identified nature of the 
data. Hospital records for patients used in the experiment were obtained from the “data 
warehouse” of a large southeastern medical school where the experiments were 
conducted. The patient charts used in the experiment are de-identified electronic 
medical records for patients served at this hospital. EMR facsimile screens with data for 
a sample de-identified patient used in the experiment are shown in appendix 1. The 
appendix 1 screen shots show a single static view of a patient’s EMR. Software used in 
the experiment dynamically updated the chart information reported in the EMR screens 
with each additional “experimental day” adding the new EMR information from another 
24 hour period included in the hospital’s EMR for a patient. 
To conduct our experiment we selected 30 representative patient charts with 
varying degrees of patient risk characteristics. We selected an equal balance of 10 low 
risk, 10 medium risk and 10 high risk patients based on the historical readmission rates 
for the procedure the patient was submitted to the hospital. In all treatments, the 
subjects were informed that they should assume that a patient was being managed at 
the appropriate standard of care while in the hospital and that the subjects were not 
being asked to speculate about additional tests or procedures that they might want to 
order. Instead, they were asked only to make a decision on whether to discharge each 
patient served on an experimental day. 
 On each experimental day, representing EMR patient data for one calendar day 
in the hospital, subjects see three patients and when one patient is successfully 
discharged (i.e., does not get readmitted) another patient is placed under the control of 
the subject. Each subject makes a total of 30 discharge decisions (including 
unsuccessful ones).  However, the number of patients being seen during the experiment, 
the duration of the experiment and the number of experimental days are all 
endogenously determined by the subject’s decisions.  Fictitious names were used for the 
patients to ensure anonymity.  
                                                        
12 Subject instructions for the experiment can be found at http://excen.gsu.edu/jccox/instructions. 
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The three treatments, representing alternative physician compensation schemes, 
in Experiment 1 are listed in the top row of Table 1: flat fee for service (FFS), 
instantaneous profit-sharing bundled (BU) payments, and deferred profit-sharing bonus 
(BO) payments. All three schedules offer payment only for successful discharges. A 
“successful” discharge decision is one that is not followed by a readmission within 30 
days.  
The first payment plan, flat fee-for-service (FFS) pays each subject $5 for each 
successful discharge decision.13 With this payment mechanism there are no rewards or 
penalties for keeping the patient fewer or more days. This payment schedule offers 
incentives for over treatment because the payment is received only for successful 
discharges while readmission probabilities may decrease with longer hospital stays.  To 
calibrate the other two payment mechanisms, we used the subject choices under the 
FFS treatment to generate payments under the P4P mechanisms that would potentially 
incentivize subjects to cost-effectively reduce the patient’s length of stay while meeting 
the CMS targeted reductions in readmission rates. We calculated the average length of 
stay (LOS) within the FFS treatment for each patient. We then used this average LOS to 
parameterize our other two payment mechanisms in a way that the payment received 
would be identical across the three treatments if the patient were to be discharged on 
the day that corresponds to its average LOS in FFS.  
 Under the bonus (BO) payment treatment subjects received a flat fee of $3 for 
each successful discharge and then a bonus payment that was awarded to them at the 
end of a period of 10 discharges as the lump-sum of all the bonuses derived for all of the 
successfully discharged patients during that period.14 The bonus was calculated such 
that each day the physician subject shortened a patient’s length of stay below the 
average LOS (across subjects) for that patient under the FFS treatment pays an extra 
$0.50 and every day beyond the average LOS under the FFS treatment comes with a 
loss of $0.50. This information was provided to subjects on their decision screens so 
they could see the schedule of bonuses. This treatment represents a deferred payment 
P4P mechanism as the performance-adjusted earnings are obtained after every 10 
discharges.  
                                                        
13 Accumulated earnings were updated at the end of each successful discharge.  The possible 
wealth effects of this payoff protocol were minimized by the independent random order of patients 
for each subject. 
14 There is a portfolio or hedging incentive within each ten periods of successful discharges. This 
incentive in the experiments reflects the incentives created by the P4P mechanism itself.  
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The bundled (BU) payment mechanism is similar in the final payment to the one 
offered under the BO treatment but the fixed payment and bonus payments are not 
separated; the payments are combined into one payment. In the BU treatment each 
subject receives an instantaneous reward or penalty for decisions within the experiment. 
As was the case under the FFS incentive structure subjects were only paid for 
successful discharges under the BO and BU P4P mechanisms. Both mechanisms, BO 
and BU provide incentives not only for good patient care, as payment is received only for 
successfully discharged patients, but also for avoiding over treatment as the payment 
decreases for every day the patient is kept in the hospital. In addition each readmission 
costs at least $1 because a readmitted patient cannot be discharged earlier than the 
third day after readmission, providing stronger incentives for higher quality of care while 
at the same time making the subject accountable for an unnecessary patient stay in the 
hospital. The average individual subject payoff in Experiment 1 was $147 and the 
experiment lasted, on average, 90 minutes. 
The probit econometric model used to construct the clinical decision support 
system developed in Cox, et al. (2014) provided an anchoring point for the experimental 
data by providing an objective measure of when a patient should be discharged 
regardless of the P4P mechanism utilized. Given the heterogeneity in the risk types 
among the 30 patient records used in the experiment we randomly selected the first 
experimental day on which the subject was asked to make a discharge decision to be 
between one and four days before the first day that the patient should have been 
discharged according to the decision support system.15 The number of preceding days 
was independently randomly selected for each of the 30 patients. Furthermore, the 
ordering of the 30 patient charts was independently randomly selected for each of the 
subjects within the experiment. 16  Any patient who was discharged could either be 
                                                        
15  A patient’s actual hospital length of stay is correlated with their readmission risk. Our 
randomization process ensures that all patient types are treated equally with regard to when a 
subject evaluates the patient chart information within the experiment.  The correlation between 
readmission risk and the hospital length of stay is controlled for in our regression analyzes with 
the inclusion of our target probability variable.  
16 To ensure that the experimental subjects’ discharge decisions were not influenced by the 
decisions of the practicing physician who actually took care of the patient, we removed the dates 
of actual discharge from the patient charts. This created the possibility for the experimental LOS 
to exceed the actual number of days observed in the EMR for a patient. To address this we 
created continuation charts for all 30 patients that imputed an extra five days of data assuming 
the data recorded in the EMR for the last day remained stable over this time period.  
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successfully discharged or readmitted. 17   In the case a patient was readmitted the 
patient was returned to the subject’s patient queue with a new set of patient data 
generated to reflect a particular complication that would generate a readmission. 
Readmitted patients were required to remain in the queue for at least two days before 
the subject could choose to discharge them again and the subject was required to 
review the patient’s chart for each of those days. Each subject was only allowed to make 
a total of 30 discharge decisions during the experiment.  
After making their discharge decisions subjects completed an online 
questionnaire that was embedded in the experiment software. The questionnaire elicited 
demographic information such as subject age, gender, academic performance and non-
academic interests (i.e., athletics, musical instruments). The questionnaire also included 
hypothetical response questions about risk attitudes to get some information about 
subjects attitudes toward risk that could affect their decision making in the presence of 
health related risks.18  After completing the questionnaire, subjects exited the lab one at 
a time to be paid in private. 
 
4. Data from Experiment 1 
A total of 100 subjects participated in Experiment 1. The distribution of subjects over the 
three treatment cells is reported in the first row of Table 1: 24 subjects participated in 
FFS payment treatment and 36 and 40 subjects participated in BO and BU payment 
treatments respectively. All of the subjects participating in the experiment were third or 
fourth year medical students at a large southeastern medical school who were in the 
clinical training phase of their medical education.19 Each subject participated in only one 
of the three treatment cells; we utilized a between-subjects design to investigate the 
treatment effects of our P4P payments, BO and BU.  
The characteristics of the subjects participating in each of the three treatments 
were similar. The overall number (48) of female participants was similar to the number 
(52) of male subjects within the experiment. The composition of males and females 
across the three P4P mechanisms were not significantly different from one another. 
                                                        
17 The daily likelihood of readmission was calculated using the probit model developed by Cox et 
al. (2014). 
18 The questionnaire can be found at 
http://excen.gsu.edu/restricted/subjectInstructions/cer/PostExperimentQuestionnaire.pdf 
19 We restricted our sample of medical students to only those in the clinical phase of their training 
to ensure they all possessed the necessary baseline information to make an informed discharge 
decision. 
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There were 13 males and 11 female subjects in the FFS treatment, 22 male and 14 
female subjects in the BO treatment and 17 male and 23 female subjects in the BU 
treatment (Pearson chi2(2)=2.69, p-value=0.261). Academic performance of subjects 
who participated in different treatments was at comparable levels. The reported average 
grade point in medical school of subjects in the FFS, BO and BU payment treatments 
were 3.58 (std=0.219), 3.57 (std=0.260) and 3.55 (std=0.284) respectively. A statistical 
test of differences across the three treatment cells failed to reject the null hypothesis that 
academic performance grades across the treatments were drawn from the same 
distribution (Kruskal-Wallis test: chi2(2) = 0.250, p-value=0.883). 
There are three measures of performance across the three treatment cells that 
we look at in our analysis: subject earnings, quality of service (readmission rate), and 
hospital length of stay. Table 2 provides descriptive statistics for each of the three 
groups of subjects in the experiment for the key variables of interest as well as a few 
demographic characteristics (collected in the post-experiment survey and referenced 
above).  We define LOS as the number of days that the physician subject retained the 
patient in their queue before discharging.  Furthermore, we do not include readmitted 
patients in the LOS calculations for two reasons: (1) these data does not precisely match 
up with the data obtained from the data warehouse due to our imputed medical 
complications, and (2) readmitted patients must be retained at least two days before a 
physician subject can consider discharging the patient.  Both of these factors may 
introduce bias in the LOS for readmitted patients. 
Comparison across payment schemes shows that both P4P compensation 
schemes reduce LOS per patient by about 1 day, increase earnings for subjects by 
about $12 while increasing readmission rates by about two to three percent.20  We next 
report several ways of describing the data and statistical analysis for significance of 
treatment effects at the individual level. 
 
4.a  Readmissions as an Indicator of the Quality of Care 
An earlier discharge is not an indicator of better discharge decision making if it 
decreases the quality of care. An indicator of the quality of care is the readmission rate 
since a premature discharge increases the likelihood of an unplanned but necessary 
                                                        
20  With respect to readmission rates, however, the null hypothesis of no effect of payment 
mechanisms on the readmission rates is not rejected by our data (Kruskal-Wallis test, 
chi2(2)=3.81, p=0.149). 
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readmission. The average readmission rates were 9% (FFS), 11% (BU) and 12% (BO). 
To investigate the treatment effects on the readmission rate we ran probit regressions 
with a binary dependent variable that takes a value of 1 if a patient is readmitted. The 
results from the regression are contained in the Experiment 1 columns of Table 3 (first 
three columns). We report the estimated marginal coefficients (and p-values in 
parentheses) with clusters at the subject level; the omitted reference group is the FFS 
treatment. The first column contains the regression results using just the treatment 
dummies within the experiment. The second column adds demographic information, 
which includes gender, whether or not the subject was a student-athlete in college or 
plays a musical instrument, the current grade point average (GPA) in medical school, the 
undergraduate GPA and the risk attitude index.  The third column includes an additional 
variable, the target probability. This variable represents a 10% reduction in the 
readmission rate relative to the historically observed procedure-specific readmission rate 
and is used to define our high, medium and low risk patient types.21 Our prior is that 
patients with a higher target readmission rate may require longer LOS as their surgical 
procedures are more complex. Our main finding is that BU compensation does not 
induce lower quality of care as the probability of readmissions is (statistically) similar to 
the one observed under FFS but the BO compensation comes with slightly higher 
readmission rates.  This gives us our first primary result: 
 
Result 1. Use of the BU payment mechanism does not significantly increase 
readmission rates but the BO induces higher readmissions. 
  
The demographic controls used in the probit regression reveal that subjects with an 
athletic or musical background had lower rates of patient readmission whereas a higher 
medical GPA is correlated with higher readmission rates.22 We next turn our attention to 
the LOS across treatments. 
 
4.b Hospital Length of Stay 
Figure 1 shows (Gaussian kernel) densities of the distributions of LOS across the three 
payment mechanisms. It suggests that the distribution of FFS has a fatter right tail than 
                                                        
21 The 10% reduction is based on the targets set by CMS discussed earlier.  The targeted 
readmission rate is less than 10% for the low risk patients, between 10% and 17% for the 
medium risk patients and greater than 17% for the high risk patients. 
22 A record as a competitive athlete or musician is selected for in medical school admissions.  
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the other two, implying a longer LOS in the FFS treatment than the BU and BO 
treatments.  The 95% C.I. of the mean of LOS for FFS ([3.85, 4.37]) does not overlap 
with the 95% C.I. of the means of LOS for the two P4P mechanisms, BU ([2.94, 3.26]) 
and BO ([2.81, 3.17]).23  
To further investigate the treatment effects on LOS we ran Censored-Normal 
regressions on the observed patient LOS using the same covariates in the probit 
regression as well as the “Start Date” for a patient as this information is observed by 
subjects within the experiment.  The Start Date is the patient’s current number of days 
within the hospital before the physician subject observed them within the experiment.  
The results from this regression with robust standard errors are reported in the left three 
columns of Table 4. The regression results indicate that both P4P compensations 
decrease LOS by slightly over one day; the estimates are robust across the three 
specifications.  This generates our second primary result: 
 
Result 2. Use of P4P compensation reduces hospital length of stay. 
 
Our data provide evidence that altering the compensation mechanism to better align 
incentives of physicians, hospitals and patients, either BU or BO, reduces the hospital 
length of stay.  However, the BU payment mechanism provides a more cost-effective 
method to meet the quality standards set forth by CMS as it reduces LOS without 
increasing readmission rates.  The BO compensation scheme reduces LOS but 
increases the rate of hospital readmission by 3% (statistically significant at the 10% level 
after controlling for subject’s idiosyncratic characteristics). 
 
5. Experiment 2: P4P Compensation and EMR+CDSS Information 
Rapid technological progress facilitated by the use of automated processes and 
computers enhances the opportunities for providing physicians with richer information on 
the health trajectories of their patients on a daily basis. A remaining question is whether 
in the presence of a richer information structure the effects of the compensation 
mechanisms on the quality of physicians’ decisions remains.  To get some insights on 
the robustness of the results reported earlier, we conducted a second experiment that is 
                                                        
23The 95% C.I. of the mean of total LOS (sum of the time before a patient was observed by a 
physician subject and the number of days that the patient was retained in the queue) for FFS 
([7.73, 8.30]) does not overlap with the 95% C.I. of the means of LOS for the two P4P 
mechanisms, BU ([6.77, 7.14]) and BO ([6.63, 7.07]).  
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identical to Experiment 1 except that the subjects were provided discharge 
recommendations and information on the likelihood of readmissions for each patient on 
each day in the hospital. 
All features of Experiment 2 are the same as Experiment 1 except the way in 
which information was presented to the subjects. Experiment 2 was conducted in an 
environment that included the clinical decision support system (CDSS) described in Cox, 
et al. (2014). In addition to the EMR information presented to subjects in Experiment 1, 
the information presented to subjects in Experiment 2 included the CDSS information 
screens and dynamically updated recommendations on whether to discharge a patient 
on each “experiment day” which corresponded to a 24 hour day in the electronic medical 
record for a patient. The CDSS makes one of three recommendations for each patient 
on each experiment day: (1) do not discharge the patient, (2) physician judgment, or (3) 
discharge the patient. Information and discharge recommendation screens for the CDSS 
are shown in Cox, et al. (2014).24  
A total of 109 subjects participated in Experiment 2. They were distinct from the 
subjects in Experiment 1. The distribution of subjects over the three treatment cells is 
reported in the second row of Table 1. All of the subjects participating in the experiment 
were third or fourth year medical students at a large southeastern medical school who 
were in the clinical training phase of their medical education. Each subject participated in 
only one of the treatment cells and we utilize a between-subjects design to investigate 
the treatment effects of the P4P mechanisms and their interaction with the two (EMR or 
EMR+CDSS) information treatments. The average earning for physician subjects in 
Experiment 2 was $159. 
 
5.a Readmissions as an indicator of the quality of care  
The average readmission rate for the FFS treatment was 8.74% and 7.69% for the two 
respective information treatments, EMR and EMR+CDSS respectively. The average 
readmission rate increased (by about 2%) for both the BU and BO payment treatments, 
but by less than that observed in the absence of information (Experiment 1). The null 
hypothesis of the readmission rates coming from the same distribution is not rejected by 
data from EMR+CDSS cells (chi2(2)=2.751, p=0.253). In the BU treatment the average 
readmission rate was 10.96% in the EMR information treatment and 9.91% under 
                                                        
24 These screens are available at: http://excen.gsu.edu/jccox/docs/CDSS-Information-and-
Decision-Screens.pdf 
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EMR+CDSS, and in the BO treatment the average readmission rate was 12.04% under 
the EMR and 9.27% under EMR+CDSS. The data reject the null hypothesis that the 
readmission rates observed in the EMR and EMR+CDSS cells come from the same 
distribution in favor of the alternative hypothesis that the CDSS decreases readmissions 
(Mann-Whitney, p=0.067; t-test, p=0.041; means are 10.80% (EMR) and 9.18% 
(EMR+CDSS)). The EMR+CDSS treatment significantly decreases readmissions 
compared to the EMR treatment. This finding is consistent with the research findings of 
Cox, et al. (2014).  
To further investigate the treatment effects on the readmission rate we ran probit 
regressions with a binary dependent variable that takes a value of 1 if a patient is 
readmitted. The results from the regression are reported in the last four columns of 
Table 3. We report the estimated marginal coefficients (and p-values in parentheses) 
with clusters at the subject level. The omitted reference group is the FFS enhanced with 
information on the daily likelihood of readmissions and CDSS recommendations (FFS-
EMR+CDSS treatment). The covariates utilized are the same covariates used in our 
analysis of Experiment 1 except for the model reported in the fourth column. In the fourth 
column we add two additional covariates, “Understay” and “Overstay.”  Understay is the 
number of days a patient is discharged before the software recommended LOS, 
whereas Overstay is the number of days a patient was retained by the physician subject 
after the recommended LOS.25  Focusing on the specification that utilizes all of the 
covariates in the model, our preferred specification, we find that relative to the 
readmissions observed under FFS-EMR+CDSS the probability of readmission did not 
increase when we utilized either the BU or BO P4P mechanisms.  
Referring to parameter estimates for the Understay and Overstay variables, we 
find that Understay and Overstay, respectively, increase and decrease readmissions; 
keeping patients one day less than recommended by the discharge recommendation 
software increases the likelihood of readmissions by 1.9% whereas keeping the patient 
one more day than recommended decreases the likelihood of readmissions by 1.1%. 
The recommended hospital length of stay (Recommended LOS) also has a significantly 
negative effect on readmissions. This gives us our third result: 
 
                                                        
25 We do not include this information in the probit regression analysis for experiment 1 because 
the recommended LOS (i.e., the CDSS) was not provided to our subject physicians in that 
experiment. 
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Result 3. Discharging a patient earlier than recommended significantly increases the 
likelihood of overall unplanned readmission; the magnitude of the effect is stronger than 
the effect of a later-than-recommended discharge. 
 
5.b Hospital Length of Stay  
We find that with the EMR+CDSS treatment, the empirical distributions of LOS and 
earnings across the three payment mechanisms are statistically different at conventional 
levels of significance26 with the bundled P4P mechanism performing best. Observed 
means of hospital LOS across the three treatments (FFS, BO, BU) are: LOS = (2.96, 
2.67, 2.08).27 Data from the EMR+CDSS treatments reveal higher efficiency (lower LOS 
as well as lower readmissions) than data from the EMR treatments, but within the 
EMR+CDSS treatments the BU (bundled) P4P mechanism is the most efficient one.  
 A decomposition of the performance of payment mechanisms over all EMR and 
EMR+CDSS treatments shows that the average observed LOS is reduced by the CDSS. 
A close inspection of figures in the “Patient LOS” row of Table 2 suggests that the use of 
the P4P mechanisms reduced the average LOS for patients with additional reductions in 
the LOS resulting from the use of the CDSS. To more rigorously investigate the 
treatment effects (in the presence of enhanced information) on LOS we ran Censored-
Normal regressions on the observed LOS using the same covariate controls as in our 
analysis of Experiment 1. The results from this regression with robust standard errors 
are reported in the last three columns of Table 4. 
 The regression results indicate that with richer information the BU-EMR+CDSS 
incentive mechanism reduces the LOS relative to the FFS-EMR+CDSS treatment, with 
the observed reduction being approximately 1 day.  However, it is worth noting that the 
FFS-EMR+CDSS treatment already generated an average reduction in the LOS relative 
to the FFS-EMR treatment of approximately one day.  Therefore, the BO-EMR+CDSS 
treatment still generated a reduction in the LOS relative to the FFS-EMR treatment.28  
                                                        
26 Kruskal-Wallis test: LOS: chi2(2)=8.15, p=0.017; Earnings: chi2(2)=38.02,p=0.0001). 
27 Observed means of total LOS (sum of the time before a patient was observed by a physician 
subject and the number of days that the patient was retained in their queue) across the three 
treatments (FFS, BO, BU) are: LOS = (6.87, 6.55, 5.98). 
28  To validate this we ran another censored regression that pooled the data from both 
experiments.  The treatment coefficients from this regression (with the list of covariates as in the 
last column of Table 4) were -1.062 (p=0.011) for BU-EMR, -1.099 (p=0.019) for BO-EMR, -1.030 
(p=0.028) for FFS-EMR+CDSS, -2.123 (p=0.000) for BU-EMR+CDSS and -1.400 (p=0.001) for 
BO-EMR+CDSS.  The omitted reference group was FFS-EMR and all coefficients were 
statistically significant different from 0 (at least at the 3% level). 
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The BU P4P mechanism combined with richer information on daily readmissions 
appears to generate the largest reductions in LOS relative to the FFS treatment without 
information. After adjusting for multiple testing, we find that the combination of the CDSS 
and bundled payments does best in reducing the hospital length of stay in our controlled 
environment. We conclude that:  
 
Result 4. Use of P4P compensation, with or without CDSS, reduces hospital length of 
stay; the effect on LOS is greater with CDSS. 
 
This final result provides evidence that altering the compensation mechanism 
provides a cost-effective method to meet the quality standards set forth by CMS if one 
combines these P4P mechanisms with the information provided by the CDSS. 
 
6. Conclusion 
The current healthcare system is in dire need of ways to increase the quality of care it 
provides while decreasing the cost of providing it. Given the recent pressure by CMS on 
hospitals to reduce their readmission rates while maintaining the current prospective 
payment system, hospitals must find creative ways to cost-effectively meet the 
standards. A potential area where hospitals can improve on their cost-effectiveness is by 
addressing the extant asymmetry between patients, hospital and physician incentives. 
Currently, physicians and hospitals do not have the same economic incentives for 
providing care to a patient. In this research we experimentally tested two alternative pay-
for-performance mechanisms that would more closely align these incentives, combined 
with providing discharge recommendations, to explore the effects of these mechanisms 
on cost-effectively meeting the quality targets recently enacted by CMS. 
Using a three-by-two experimental design defined over three payment 
mechanisms (fee-for-service, bonus and bundled payments) and two information 
conditions (EMR and EMR+CDSS), our research indicates that the P4P mechanisms 
used in our experiment combined with the clinical decision support system (Cox et al. 
2014) can be used to make more cost-effective and evidence-based hospital discharge 
decisions. The largest reduction in average LOS resulted from the bundled payment 
mechanisms combined with the CDSS information, where the LOS fell by nearly two 
days. This reduction in LOS did not come with an increase in the probability of 
readmission. Therefore, the bundled payment mechanism proved to be a very cost-
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effective mechanism to reduce LOS and meet readmission targets, especially when 
supported by the CDSS. 
Although not of the same magnitude as those observed under the bundled 
payment mechanism, the bonus payment mechanism with the CDSS resulted in a 
reduction in LOS of 1.4 days. Across the treatments the bonus and bundled payment 
models reduced LOS by at least one day.  Therefore, utilizing P4P mechanisms to better 
align physician, hospital (and indirectly patient) interests is a cost effective way to 
achieve the quality targets set forth by CMS. In addition, the information provided by the 
clinical decision support system (CDSS) reduced LOS without increasing readmission 
rates. With both fee-for-service and bundled payment compensation use of the CDSS 
reduced LOS by approximately one day whereas the additional reduction in LOS with 
the bonus mechanism was smaller (approximately 0.4 days). 
Our estimates suggest a sizeable cost savings to a hospital if it utilizes the 
bundled payment mechanism as well as the CDSS. In fact, each provides a cost-
effective way to meet Medicare targets in that they have additive effects. This said, there 
are a few limitations that are worth mentioning. First, the utilization of either of the P4P 
mechanisms used in our experiment will require buy-in from both hospitals and 
physicians in order for it to be effective. The latter of these two parties may find these 
mechanisms unpalatable because they more concretely link their compensation to the 
cost of care and force them to make cost-benefit calculations that they may argue 
compromise physician autonomy. Again, piloting of these P4P mechanisms would be 
required before full-scale utilization. Second, the CDSS requires additional validation 
and piloting before it can be fully integrated within a hospital electronic medical records 
system. This is something we are researching at the current time.  
In summary, this research suggests that there are a number of ways in which 
hospitals can cost-effectively reduce their readmission rates and meet the quality metric 
set forth by CMS. Continued research in this area is needed and we hope our findings 
stimulate an increased use of experimental economic methods to meet the challenges of 
the healthcare sector. 
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FIGURES 
 
Figure 1: Hospital Length of Stay (LOS in the Experiment) across P4P Mechanisms. 
Each line represents the Gaussian kernel density of the LOS by payment mechanism in 
Experiment 1. FFS: fee-for-service; BO: bonus payment; BU: bundled payment. 
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TABLES 
 
Table 1. Treatments and Number of Subjects.  Experiment 1 combines the electronic 
medical treatment (EMR) with the fee-for-service (FFS), bonus (BO) and bundled (BU) 
payment mechanisms.  Experiment 2 adds the clinical decision support system (CDSS) 
to the EMR and combines them with the fee-for-service (FFS), bonus (BO) and bundled 
(BU) payment mechanisms. 
 
 Fee-for-
Service (FFS) 
Bonus Payment 
(BO) 
Bundled Payment 
(BU) 
 
Experiment 1: EMR 
 
 
24 
 
 
36 
 
 
40 
 
 
Experiment 2: EMR+CDSS 
 
23 
 
 
43 
 
 
43 
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Table 2: Descriptive Statistics by Treatment: Experiment 1 uses the electronic 
medical record (EMR) information combined with the three payment mechanisms: fee-
for-service (FFS), bonus (BO) and bundled (BU).  Experiment 2 uses the EMR and 
clinical decision support software (CDSS) combined with the three payment 
mechanisms: FSS, BO and BU. Demographic information includes the percentage 
female, age and both their undergraduate grade point average (GPA) as well as their 
medical GPA, both on a 4.0 scale.  Earnings are total earnings in U.S. dollars. 
Performance measures include the rate of readmission following a patient’s discharge in 
the experiment and the patient’s length of stay (LOS).  Means for each variable are 
reported in the table with standard deviations reported in parentheses. 
  
 Experiment 1 Experiment 2 
Treatment FFS BO BU FFS BO BU 
# of Subjects 24 36 40 23 43 43 
Demographics       
Percentage Female 0.458 
(0.509) 
0.389 
(0.494) 
0.575 
(0.506) 
0.652 
(0.487) 
0.581 
(0.499) 
0.488 
(0.506) 
Age 26.917 
(2.225) 
26.278 
(1.717) 
26.200 
(1.488) 
26.739 
(3.828) 
26.186 
(2.510) 
33.279 
(4.000) 
Undergraduate GPA 3.660 
(0.219) 
3.704 
(0.200) 
3.690 
(0.192) 
3.701 
(0.195) 
3.713 
(0.174) 
3.701 
(0.256) 
Medical GPA 3.575 
(0.219) 
3.571 
(0.260) 
3.546 
(0.284) 
3.545 
(0.241) 
3.579 
(0.255) 
3.653 
(0.298) 
Subjects’ Earnings       
 137.500 
(8.341) 
149.194 
(24.425) 
150.588 
(19.352) 
139.130 
(7.635) 
160.895 
(17.315) 
167.523 
(16.230) 
Performance       
Readmission Rate 0.087 
(0.283) 
0.120 
(0.326) 
0.110 
(0.313) 
0.077 
(0.267) 
0.093 
(0.290) 
0.099 
(0.299) 
Patient LOS 4.111 2.993 3.099 2.960 2.667 2.078 
 (3.403) (2.885) (2.671) (2.447) (1.973) (1.545) 
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Table 3: Probit Regressions for Readmissions: Left three columns contain regression 
results (marginal effects) for Experiment 1.  The right four columns contain regression 
results for Experiment 2.  Additional variables in the probit regressions include: Female: 
binary indicator for female gender; Athlete: binary indicator for whether or not they were 
a student-athlete in college; Musical: binary indicator for playing a musical instrument; 
GPA: grade point average in medical school and in undergrad; Risk Attitudes Index: 
subjects risk index from post-experiment survey; Recommended LOS: The CDSS 
recommended LOS for the patient; Understay: number of days discharged before the 
CDSS recommended LOS; Overstay: number of days discharged after the CDSS 
recommended LOS; Target Probability: the target probability calculated by the CDSS. 
Robust p-value in parentheses: *** p<0.01, ** p<0.05, * p<0.1. 
 
Treatments 
Experiment 1 
(EMR) 
Experiment 2 
(EMR+CDSS) 
BU 0.024 
(0.173) 
0.020 
(0.235) 
0.020 
(0.228) 
0.023 
(0.144) 
0.035** 
(0.033) 
0.034** 
(0.035) 
0.024 
(0.120) 
BO 0.035* 
(0.062) 
0.028* 
(0.098) 
0.030* 
(0.077) 
0.017 
(0.295) 
0.025 
(0.161) 
0.024 
(0.168) 
0.022 
(0.159) 
Demographics        
Female  -0.010 
(0.419) 
-0.010 
(0.396) 
 0.006 
(0.557) 
0.006 
(0.589) 
0.010 
(0.323) 
Athlete  -0.031** 
(0.020) 
-0.031** 
(0.020) 
 -0.013 
(0.326) 
-0.013 
(0.309) 
-0.007 
(0.560) 
Musical  -0.027** 
(0.035) 
-0.026** 
(0.040) 
 -0.007 
(0.497) 
-0.007 
(0.519) 
-0.004 
(0.692) 
Medical GPA  0.064*** 
(0.004) 
0.065*** 
(0.003) 
 0.012 
(0.485) 
0.010 
(0.575) 
0.007 
(0.697) 
Undergraduate GPA  -0.002 
(0.962) 
-0.000 
(0.993) 
 -0.033 
(0.109) 
-0.030 
(0.127) 
-0.027 
(0.147) 
Risk Attitude Index  -0.000 
(0.975) 
-0.000 
(0.971) 
 -0.003 
(0.389) 
-0.002 
(0.422) 
-0.003 
(0.360) 
Other        
Recommended LOS       -0.009*** 
(0.000) 
Understay       0.019*** 
(0.000) 
Overstay       -0.011** 
(0.036) 
Target Probability   0658*** 
(0.000) 
  0.662*** 
(0.000) 
0.762*** 
(0.000) 
Observation 2,742 2,742 2,742 3,039
 2,985a 2,985a 2,985a 
Log-Likelihood -936.0 -928.9 -908.7 -930.8 -904.4 -878.9 -862.4 
aIn experiment 2, two subjects have missing information on (medical) GPA; a total of 54 discharge decisions 
on regular patients made by them were deleted in the last two models with controls of demographics.  
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Table 4: Censored-Normal Regressions for Patient Length of Stay: Left three 
column contains regression results for Experiment 1.  The right three columns contain 
regression results aggregating the data from Experiment 2.  Dependent variable is the 
LOS within the experiment.  Additional variables in the regressions include: Female: 
binary indicator for female gender; Athlete: binary indicator for whether or not they were 
a student-athlete in college; Musical: binary indicator for playing a musical instrument; 
GPA: grade point average in medical school and in undergrad; Risk Attitudes Index: 
subjects risk index from post-experiment survey; Recommended LOS: The CDSS 
recommended LOS for the patient; Target Probability: the target probability calculated by 
the CDSS. Robust p-value in parentheses: *** p<0.01, ** p<0.05, * p<0.1. 
 
Treatments 
Experiment 1 
(EMR) 
Experiment 2 
(EMR+CDSS) 
BU -1.075** 
(0.014) 
-1.064** 
(0.013) 
-1.089** 
(0.011) 
-0.960*** 
(0.003) 
-0.962*** 
(0.005) 
-0.976*** 
(0.004) 
BO -1.221** 
(0.013) 
-1.056** 
(0.029) 
-1.066** 
(0.028) 
-0.280 
(0.418) 
-0.234 
(0.516) 
-0.244 
(0.496) 
Demographics       
Female  0.322 
(0.354) 
0.314 
(0.365) 
 0.326 
(0.110) 
0.338* 
(0.100) 
Athlete  -0.157 
(0.696) 
-0.161 
(0.690) 
 0.341 
(0.117) 
0.351 
(0.109) 
Musical  1.062*** 
(0.002) 
1.068*** 
(0.002) 
 0.256 
(0.243) 
0.249 
(0.259) 
Medical GPA  -0.804 
(0.187) 
-0.814 
(0.184) 
 -0.126 
(0.759) 
-0.122 
(0.766) 
Undergraduate GPA  -0.178 
(0.832) 
-0.217 
(0.798) 
 0.275 
(0.601) 
0.274 
(0.601) 
Risk Attitude Index  0.011 
(0.926) 
0.010 
(0.929) 
 -0.006 
(0.930) 
-0.009 
(0.899) 
Other       
Target Probability   7.235*** 
(0.000) 
  3.235*** 
(0.000) 
Start Date   -0.439*** 
(0.000) 
  -0.316*** 
(0.000) 
Constant 3.871*** 
(0.000) 
6.674* 
(0.069) 
7.534** 
(0.043) 
2.821*** 
(0.000) 
1.864 
(0.389) 
2.624 
(0.223) 
Observations 2,742 2,742 2,742 3,093 2,985a 2,985a 
aIn experiment 2, two subjects have missing information on (medical) GPA; a total of 54 discharge decisions 
on regular patients made by them were deleted in the last two models with controls of demographics.  
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Appendix 1. EMR Facsimile Screens 
 
 
 
Figure A1: Inpatient Summary 
 
 
 
Figure A2: Laboratory Data 
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Figure A3: Orders 
 
 
 
 
Figure A4: Vital Signs 
